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Abstract 
 
High protein diets suppress appetite and facilitate weight loss. However, they are 
difficult to adhere to. Understanding the mechanisms by which protein suppresses 
appetite may establish targets for more acceptable interventions to treat or prevent 
obesity.  
 
Receptor systems that respond to amino acids, the products of protein digestion, 
have been identified. However, the specific mechanisms regulating protein-induced 
satiety are unknown. Previous work within our laboratory has investigated the effect 
of specific amino acids which act as ligands for the following G-protein coupled 
receptors: CaR, T1R1/T1R3 and GPRC6A on food intake in rodents.  
 
L-cysteine activates the CaR, the T1R1/T1R3 and the GPRC6A.  A diet that includes 
high levels of whey protein, which contains high levels of L-cysteine, has been 
reported to be more satiating and to suppress circulating levels of the orexigenic 
hormone ghrelin to a greater extent than other types of protein in humans.  Pilot 
studies suggested that ligands for the GPRC6A receptor can reduce food intake in 
rodents, and that this effect is at least partly mediated by a reduction in circulating 
ghrelin levels.   
 
The putative role of L-cysteine in food intake in humans was investigated.  The effect 
of a high protein meal on circulating levels of cysteine was determined.  
Subsequently, the time course of changes in the circulating levels of L-cysteine 
following oral consumption of L-cysteine was established.  Finally, the effects of 
different doses of cysteine on subjective assessment of appetite and acute food 
intake were investigated.  These studies suggested that oral administration of L-
cysteine at 0.04 or 0.07g/kg resulted in supraphysiological levels of L-cysteine in 
circulation.  Oral administration of L-cysteine significantly influenced subjective 
markers of appetite compared to vehicle or glycine controls, but did not affect food 
intake. These data suggest that L-cysteine may be suitable for manipulating appetite 
in humans.    
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1.1.  Background 
 
Obesity, its complications and the associated mortality are major global public health 
issues. The World Health Organisation (WHO) has declared that global childhood 
and adult obesity levels have reached epidemic proportions.  Once considered a 
problem only in developed countries, obesity is now also on the rise in developing 
countries (WHO, 2012).  It is predicted that up to 58% of the world‟s adult population 
will be overweight or obese by 2030 (Kelly et al., 2008). Worldwide, 2.8 million 
people die annually as a result of being overweight and an estimated 35.8 million 
(2.3%) of global disability-adjusted life years are caused by overweight or obesity 
(WHO, 2009).  Obesity is associated with cardiovascular disease, type 2 diabetes 
and certain forms of cancer, and the rise in the prevalence of obesity has 
consequently been paralleled by rises in these chronic diseases. The Foresight 
report highlighted appetite regulation as a major target in the dietary treatment of 
obesity (Butland, 2008).  Of particular interest is the concept of functional foods or 
novel products, which aim to potentiate satiety. The goal is to design foods or dietary 
regimens that cause an increased sense of fullness and encourage the individual to 
stop eating sooner, thus reducing total energy intake (Hill and Peters, 2002). 
 
 
1.2. Energy homeostasis 
 
Various homeostatic mechanisms exist to maintain a balance between food intake 
and energy expenditure.  Energy homeostasis is a result of coordination of central 
neural signals and peripheral neural and hormonal signals, as shown in Figure 1.1.  
Stability of body weight is achieved by maintaining a balance between food intake 
and energy expenditure.  
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Figure 1.1.  The pathways by which gut hormones regulate energy 
homeostasis. 
PVN: paraventricular nucleus; ARC: arcuate nucleus; NPY: neuropeptide Y; AgRP: Agouti-
related protein; POMC: pro-opiomelanocortin; PP: pancreatic polypeptide; PYY: peptide 
tyrosine tyrosine; GLP-1: glucagon-like peptide-1; OXM: oxyntomodulin.  From: Murphy KG 
& Bloom SR (2006) Gut hormones and the regulation of energy homeostasis. Nature 444: 
854-9 (Murphy and Bloom, 2006) 
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The hypothalamus and the brain stem are the major brain regions involved in the 
regulation of food intake and energy expenditure. The hypothalamus is located at the 
base of the brain just below the thalamus, where it receives afferent signals from the 
periphery and from other parts of the central nervous system (CNS). The brain stem 
is at the posterior of the brain, and is structurally continuous with the spinal cord. The 
brain stem contains the dorsal vagal complex, which receives neural innervations 
from the gastrointestinal tract, and includes the area postrema (AP), a part of the 
brainstem which lies outside the blood-brain barrier and hence is a direct target for 
peripheral satiety signals.  Complex neuronal circuitry exists between the brainstem 
and hypothalamus.   
 
Signalling from the periphery to these brain centres can thus be in the form of neural 
or hormonal signals. Vagal neural pathways mediate specific chemosensory 
responses from the gut. Animal and human studies show that inhibiting these 
pathways via vagotomy or afferent denervation can attenuate the inhibition of gastric 
emptying and food intake which takes place when nutrients enter the gastrointestinal 
tract (Wilkinson and Johnston, 1973, Roze et al., 1977, Raybould and Holzer, 1992, 
Schwartz et al., 1993).  Intestinal nutrients initiate signals from gut epithelial cells via 
vagal afferent endings, with subsequent effects on the central nervous system.  
These signals activate gastric vagal motor neurons, which cause relaxation of the 
proximal stomach (Horowitz and Dent, 1991, Azpiroz and Malagelada, 1987), inhibit 
antral contractions, and stimulate tonic and phasic pyloric pressures. 
 
Hormonal signals are coordinated centrally along with neural signals from the gut 
(Schwartz et al., 2000).  Gut hormones can act via vagal pathways from the 
gastrointestinal tract to the brain (Schwartz, 2000, Moran, 2000), or can act directly 
on central neurones (Kalra et al., 1999, Cone et al., 2001).  Meal anticipation and the 
presence of nutrients in the upper part of the gut stimulate gut hormone and 
neurotransmitter release (Schwartz, 2000).  
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1.3. Nutrient sensing 
 
Recent research has highlighted the importance of the gut-brain axis and nutrient 
sensing in the regulation of food intake and metabolism (Stanley et al., 2005, 
Chaudhri et al., 2006, Badman and Flier, 2005).  The body‟s nutrient sensors have 
multiple functions, including the detection of nutrient availability and the regulation of 
post-absorption processes.  Sensing of nutrients in the gut and the brain may also 
play a role in regulating food intake (Blouet and Schwartz, 2010, Dyer et al., 2003, 
Raybould, 2007, Layer et al., 1995, Dumoulin et al., 1998). 
 
1.3.1. The role of the hypothalamus in central nutrient sensing 
The central nervous system has been suggested to act as a rheostat of acute 
nutrient availability (Blouet and Schwartz, 2010).  The hypothalamus contains a high 
concentration of nutrient-sensing elements and is thought to be the main centre for 
coordination of nutrient-related signals.  Some of the key hypothalamic nuclei, 
namely the arcuate, ventromedial and lateral nuclei, are thought to respond 
specifically to glucose, fatty acids, amino acids and other fuel-related stimuli.  Within 
these neuronal populations, nutrients can act as signalling molecules to directly elicit 
neurochemical responses which influence energy intake and nutrient utilisation 
(Blouet and Schwartz, 2010).  The arcuate nucleus-median eminence area is 
incompletely isolated from the circulation by the blood-brain barrier, allowing arcuate 
neurons to directly respond to circulating nutrients.  The arcuate nucleus is therefore 
thought to represent an important area for central nutrient sensing.  
 
1.3.2. The role of the gut in peripheral nutrient sensing 
Peripheral nutrient sensing can occur in the gut, liver or portal circulation, and the 
resulting signals can be transmitted to the brain via neural signalling and/or the 
release of gastrointestinal hormones.   Specific nutrients are detected peripherally to 
inhibit food intake in both humans and animal models (Greenberg et al., 1990, 
Matzinger et al., 2000).  Chemosensory cells present in the gut epithelial lining 
include enterocytes, brush cells and enteroendocrine cells, all of which have direct 
contact with the intraluminal contents.  Enteroendocrine cells play a specialised role 
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in luminal nutrient sensing, although they represent less than 1% of epithelial cells 
within the gut.  Peptide hormones are released from secretory granules located in 
the basal cytoplasm of this cell type (Hofer et al., 1999).  These cells are often 
situated deeper within the gut wall than enterocytes, and many have processes 
which extend to the intestinal lumen via which they can directly sense luminal 
contents.  Those enteroendocrine cells which do not extend to the epithelial surface 
are controlled indirectly by the luminal content via neural and hormonal signals, and 
directly by circulating nutrients absorbed from the gut (Sternini et al., 2008).  
 
1.3.3. Carbohydrate sensing 
Carbohydrates consumed in the diet are digested to form sugars (glucose, fructose, 
and galactose) that are absorbed via enterocytes in the gut (Wright et al., 2003).  
Sugar type and rate of digestion have a significant effect on nutrient sensing 
pathways.  Digestion and absorption of ingested carbohydrate is coordinated by 
sugar sensing in the gastrointestinal tract, which regulates nutrient absorption, 
hormone release and gut motility, and which sends satiation signals to the brain 
(Dyer et al., 2003, Raybould, 2007).  Evidence from human studies demonstrates 
that a centrally detected drop in blood glucose can alter peripheral glucose 
management. This is mediated by mechanisms including the secretion of counter-
regulatory hormones from the pancreas, the release of catecholamines from the 
adrenal glands (Mitrakou et al., 1991, Taborsky et al., 1998), and the activation of 
the autonomic nervous system to drive hepatic glucose production (Perseghin et al., 
1997). Central infusion of glucose directly into the hypothalamus reduces food intake 
and body weight (Davis et al., 1981, Panksepp and Rossi, 1981), suggesting that 
central glucose sensing may also play a role in appetite regulation.  
 
1.3.4. Lipid sensing 
Following a meal, fat is digested to form fatty acids and monoglycerides, which are 
then absorbed.   The length of the hydrocarbon chain in a fatty acid determines 
whether it is described as short (tails of <6 carbons), medium (6-12 carbons) or long 
(13-21 carbons). Short and medium-chain fatty acids enter the hepatic portal 
circulation directly through the intestinal capillaries, but long-chain fatty acids 
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(LCFAs) enter the systemic circulation via the lymphatic system, bypassing the portal 
circulation, and hence their systemic concentrations are more representative of 
acute lipid intake.  Increasing the concentration of LCFAs within the central nervous 
system, and particularly within the hypothalamus, inhibits both food intake and 
hepatic glucose production (Lam et al., 2005, Caspi et al., 2007).  The presence of 
lipids in the gut alters gut hormone release. LCFAs sensed in the gut stimulate the 
secretion of cholecystokinin (CCK) from duodenal I-cells (Moran and Kinzig, 2004).  
CCK delays gastric emptying, stimulates contraction of the gall-bladder to release of 
bile acids into the duodenum, and stimulates pancreatic enzyme production and 
secretion, allowing the digestion and absorption of dietary lipids (Cheung et al., 
2009).  CCK also increases satiation via CCK-A receptors on vagal afferents which 
signal via the nucleus of the solitary tract (NTS) in the brainstem (van de Wall et al., 
2005).  LCFAs also stimulate the release of the anorectic gut hormones peptide YY 
(PYY) and glucagon-like peptide-1 (GLP-1) from human enteroendocrine cells 
(Stoeckel et al., 2008).  In addition, oral administration or direct gut administration of 
free fatty acids (FFAs) causes a rise in GLP-1 and insulin levels in rodent models, a 
process which may be mediated free fatty acid receptors (Hirasawa et al., 2005).  
Recent evidence shows duodenal lipid sensing can activate a gut-brain-brown 
adipose tissue axis to regulate thermogenesis (Blouet and Schwartz, 2012). 
   
 
1.4. Protein and satiety 
 
Protein has a satiating effect greater than other macronutrients (Porrini et al., 1997, 
Reid and Hetherington, 1997, Trigazis et al., 1997, Bensaid et al., 2002, Anderson 
and Moore, 2004, Halton and Hu, 2004).  High protein diets inhibit food intake, 
facilitate weight loss and improve body composition in animal models and humans 
(Potier et al., 2009, Harper and Peters, 1989, Jean et al., 2001, Morens et al., 2000, 
Morens et al., 2001, Hannah et al., 1990, Kinzig et al., 2007).  These effects are not 
secondary to changes in palatability; studies have demonstrated that ingestion of 
high protein diets does not cause conditioned taste aversion and that protein 
ingestion leads to typical behavioural satiety sequences (Harper and Peters, 1989, 
19 
 
 
Bensaid et al., 2003). However, high protein diets are difficult to adhere to (Sargrad 
et al., 2005), and the mechanisms by which a high protein diet regulates food intake 
are largely unknown.  
 
There is evidence that protein influences gastrointestinal hormones to alter satiety. 
Protein has been reported to increase levels of anorectic gut hormones (Hall et al., 
2003, Calbet and Holst, 2004, Nilsson et al., 2004, Batterham et al., 2006).  
Following a meal, intestinal L-cells release the gut hormones GLP-1, PYY and 
oxyntomodulin (OXM) which act on central appetite centres to control eating (Stanley 
et al., 2004).  A high protein meal increases circulating concentrations of both PYY 
and GLP-1 in normal weight humans (van der Klaauw et al., 2012).  High protein 
meals are associated with significantly higher PYY responses in both lean and obese 
humans when compared to high-fat and high-carbohydrate diets (Batterham et al., 
2006).  Ghrelin is an orexigenic peptide hormone primarily synthesised in the 
stomach (Kojima et al., 1999). There is conflicting evidence regarding the effect of 
protein on ghrelin.  Circulating ghrelin levels increase with fasting, and decrease 
post-prandially (Cummings et al., 2001, Tschop et al., 2001), and ghrelin 
administration increases food intake in both animals and humans (Wren et al., 2001, 
Wren et al., 2000).  Some reports have suggested that protein ingestion has a 
smaller suppressive effect on plasma ghrelin concentrations than ingestion of other 
macronutrients (Erdmann et al., 2003, Greenman et al., 2004). However, more 
recent studies provide strong evidence that protein can suppress post-prandial 
circulating ghrelin levels more potently and/or for longer than carbohydrates (Al Awar 
et al., 2005, Blom et al., 2006, Tannous dit El Khoury et al., 2006, Bowen et al., 
2006a, Bowen et al., 2006b, Leidy et al., 2007, Foster-Schubert et al., 2008).  The 
reasons for these discrepancies remain unclear, but may be related to protein 
composition.   
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1.5. Amino acid sensing receptors 
 
There are three members of the G-protein coupled receptor (GPCR) family class C 
known to promiscuously bind a number of L-amino acid ligands, and thus suited to 
detecting the varied products of protein digestion.  These receptors are the calcium-
sensing receptor (CaR), the T1R1/T1R3 heterodimeric receptor and the GPRC6A 
receptor.  
 
The primary ligands of the CaR are calcium ions, but the CaR can also respond to L-
amino acids, in particular the aromatic amino acids.  The global CaR knockout 
mouse has a severe phenotype which includes severely dysfunctional calcium 
homeostasis, retarded growth and premature death (Kuang et al., 2005), making it 
difficult to establish whether the CaR has a physiological role in energy homeostasis.  
More recently, a gut-specific CaR knockout mouse has been developed, which 
suggests the CaR plays a role in regulating cell growth and proliferation in the gut 
(Rey et al., 2012) 
 
The functional units of the T1R1 receptor class are dimers comprised of two of three 
different subunits: T1R1, T1R2, and T1R3. The T1R1/T1R3 heterodimer acts as an 
L-amino acid taste receptor and is broadly activated by aliphatic amino acids. The 
T1R1/T1R3 heterodimer has been identified in the gut, where it can act as a luminal 
sensor for certain L-amino acids, resulting in release of gut hormones (Daly et al., 
2012).  However, targeted deletion of the T1R1 or the T1R3 receptor in the mouse 
on a normal diet does not influence body weight or food intake (Zhao et al., 2003).   
 
GPRC6A is a recently cloned receptor expressed in a number of tissues, including 
the brain, where it is found in the hypothalamus (Wellendorph et al., 2009, Kuang et 
al., 2005, Wellendorph et al., 2007, Wellendorph and Brauner-Osborne, 2004, Pi et 
al., 2005). Mice lacking GPRC6A have a complex metabolic phenotype that includes 
alterations to the reproductive axis, glucose homeostasis, and kidney and bone 
function (Pi et al., 2008). Interestingly, GPRC6A knockout mice have hepatic 
steatosis and a significantly higher percentage body fat than wild-type littermates, 
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suggesting that GPRC6A may regulate energy homeostasis and adiposity. The 
GPRC6A has been proposed as a nutrient sensing receptor (Wellendorph et al., 
2009), and  has recently been identified in the gastrointestinal tract (Haid et al., 
2011a).    
 
 
1.6. Pilot data from our laboratory 
 
Receptor systems that respond to amino acids, the products of protein digestion, 
have been identified. However, the specific mechanisms regulating protein-induced 
satiety are unknown. Previous work within our laboratory has investigated the effect 
of specific amino acids which act as ligands for the CaR, T1R1/T1R3 and GPRC6A 
on food intake in rodents.  
 
The GPRC6A is responsive to between 6 and 8 of the proteinogenic amino acids, 
including cysteine and lysine (Kuang et al., 2005, Wellendorph et al., 2005, 
Christiansen et al., 2007, Wellendorph et al., 2007). It does not respond to leucine, 
which has previously been suggested to play a role in protein induced satiety 
(Ropelle et al., 2008, Blouet et al., 2008). Cysteine is a non-essential amino acid 
found in high protein foods, including cereals, whey protein, and meat and dairy 
products. Cysteine activates the CaR, the T1R1/T1R3 and the GPRC6A 
(Christiansen et al., 2007, Nelson et al., 2002, Conigrave et al., 2000). A diet that 
includes high levels of whey protein has been reported to be more satiating and to 
suppress circulating ghrelin levels to a higher extent than other types of protein in 
humans (Bowen et al., 2007, Veldhorst et al., 2009).  
 
Pilot studies suggested that ligands for the GPRC6A receptor can reduce food intake 
in rodents, and that this effect is at least partly mediated by a reduction in circulating 
ghrelin levels.  
 
Oral administration of cysteine significantly reduced food intake in rats. The effect of 
cysteine on food intake appeared specific, as behavioural analysis showed that high 
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doses of cysteine did not alter behaviour, other than to reduce feeding behaviour. 
Oral administration of cysteine significantly suppressed circulating levels of the 
gastric hormone ghrelin, but had no effect on circulating levels of insulin, PYY or 
GLP-1.  
 
The studies described in this thesis investigated the putative role of cysteine in food 
intake in humans. I wanted first to determine the circulating levels of cysteine 
achieved following a high protein meal, to better place subsequent cysteine 
administration studies in a physiological context. These subsequent studies would 
then establish the effect of cysteine on subjective appetite and food intake.  
 
 
1.7. Hypotheses 
 
1.7.1. Part A: 
A high protein meal will cause a time-dependent increase in circulating levels of 
specific amino acids. 
 
1.7.2. Part B: 
Oral administration of cysteine will cause a time-dependent increase in circulating 
levels of cysteine. 
 
1.7.3. Part C: 
In normal and overweight subjects, increasing doses of cysteine will acutely reduce 
hunger and food intake in a dose-dependent fashion compared to controls. 
 
 
1.8. Aims 
 
1.8.1. Part A: 
To determine the time course of the increase in circulating levels of cysteine 
following a high protein meal. 
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1.8.2. Part B: 
To determine the time course of the increase in the circulating levels of cysteine after 
oral consumption. 
To determine the effect of different doses of cysteine on subjective assessment of 
appetite, using visual analogue scales.  
To determine the effect of different doses of cysteine on circulating levels of gut 
hormones. 
 
1.8.3. Part C: 
To determine the effect of different doses of cysteine on acute food intake after an 
overnight fast compared to a vehicle control. 
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2.1. Amino acids 
 
Amino acids were purchased from SynPharma International Ltd (Horsham, UK).  
Amino acid drinks were prepared by mixing 20 mL of Bottlegreen ginger and 
lemongrass cordial (Gloucester, UK) with 180 mL of water and combining with amino 
acid.  Vehicle control was cordial and water alone. 
 
 
2.2. Subjects  
 
2.2.1. Subject recruitment 
All subjects were recruited by advertisement.  Potential subjects were screened to 
exclude those with disordered eating, as assessed by the SCOFF questionnaire 
(Morgan et al., 1999) and Eating Attitudes Test (Garner et al., 1982), and those with 
a high level of restrained eating, as assessed by the standard Dutch Eating 
Behaviour Questionnaire (Van Strien et al., 1986). During the screening visit for Part 
C, a sample of the study meal was provided, and an assessment of palatability was 
made using a nine-point hedonic scale. Subjects who disliked the study meal or 
rated the study meal as „like extremely‟ were also excluded.   
 
Part A: 
Five healthy volunteers (2 male, 3 female), with mean age 37.8 years (range 28 - 57) 
and mean body mass index (BMI) 24.7 kg/m2  (range 21.1 – 32.9) were recruited for 
this study. Each subject attended one study day where they ate a high protein meal. 
Part A did not require a power calculation, as it was a descriptive pilot study.   
 
Part B: 
Seven healthy volunteers (2 male, 5 female) with mean age 33.9 years (range 20 – 
57) and mean BMI 24.3 kg/m2 (range 20.4 – 32.9) were recruited for this study. Each 
subject attended four study days where they consumed a dose of L-cysteine (either 
0.04 g/kg or 0.07 g/kg), L-glycine (0.04 g/kg or 0.07 g/kg) or vehicle control at each 
visit.   Part B did not require a power calculation, as it was a descriptive pilot study.  
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Part C:  
Twelve normal and overweight or obese but otherwise healthy volunteers (5 male, 7 
females), aged 18 - 58 years were recruited for this crossover study. Each subject 
attended 6 study days (receiving vehicle control and then either 0.04 g/kg or 0.07 
g/kg of L-cysteine or L-glycine).  It was predicted that a sample size of 17 would 
have a 90% power to detect a difference in mean calorie intake of 1200kJ (a 
difference of 20% between treatments) assuming a within-subject standard deviation 
of 1268kJ, at a significance level of 1%.   However, subsequent preclinical data 
suggested that cysteine would not prove useful as a treatment for obesity, and thus 
this part of the study was terminated after only 11 subjects had completed the 
protocol.  
 
The research was approved by the West London Research Ethics Committee 
(reference number 11/H0707/7).  All subjects gave written informed consent, and the 
research was planned and performed in accordance with the Declaration of Helsinki.  
 
2.2.2. Inclusion criteria 
Inclusion criteria were: male or female, aged 18 to 60 years (inclusive), normal and 
overweight/obese people as classified by a BMI 18.5-35 kg/m2 (inclusive) who were 
otherwise healthy (based on a pre-study assessment) and people willing and able to 
give written informed consent and to understand, participate and comply with the 
study requirements. 
 
2.2.3. Exclusion criteria 
Exclusion criteria were: treatment with any medication that might have affected the 
study outcome (e.g. medication affecting appetite regulation and/or blood flow), 
haemorrhagic disorders and anticoagulant treatment, inborn errors of metabolism, 
hepatic impairment as defined by screening visit liver function tests (aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) or gamma-glutamyl 
transpeptidase (GGT) of three times the upper normal reference limit), current 
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pregnancy or breast feeding, delivery within the last year, significant intercurrent 
disease or history of clinically significant disease of any type, in particular liver, 
kidney, or heart disease, any form of diabetes mellitus or psychiatric illness, history 
of cancer (excluding skin cancer), history of severe or multiple allergies, severe 
adverse drug reaction or leucopaenia, smokers, regular drinkers of more than three 
units of alcohol daily, subjects who had taken amino acid supplements either 
continuously or intermittently in the preceding 12 months, history of, or current 
evidence of, abuse of alcohol or any drug substance, licit or illicit, regular intake of 
over-the-counter medication (other than the occasional paracetamol/aspirin), poor 
compliers or subjects unlikely to attend, and blood donation within the 12 week 
period before the initial study dose.   
 
 
2.3. Part A: Effect of a high protein meal on circulating levels of amino acids 
in healthy human subjects 
 
After the screening appointment subjects were asked to attend one study session, 
during which they were asked to eat a high protein meal (400g of cooked chicken 
breast consisting of 93.2g protein, 1.6g carbohydrate and 5.2g fat) and have blood 
samples taken.  A schematic representation of a study day for Part A is illustrated in 
Figure 2.1. 
 
Subjects were asked to attend each study day following an overnight fast. They were 
asked to refrain from taking strenuous exercise and drinking alcohol for twenty-four 
hours before the study visit. They were asked not consume any food or drink with the 
exception of water from 2100h on the evening prior to the study day and to consume 
identical evening meals at 2000h on the evening before the study visit. 
 
On the study day, the female subjects were asked to provide a urine specimen in 
order to perform a pregnancy test.  The subjects then had an intravenous cannula 
placed in their arm and serial blood sampling beginning at t=15 minutes and 
continuing for the remainder of the study day at the time points indicated in figure 
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2.1. They were also asked to complete visual analogue scales (VAS) that rated 
hunger, satiety and nausea at these time points (Flint et al., 2000b, Stubbs et al., 
2000). The VAS consisted of 100 mm lines with text expressing the most positive 
and the most negative rating for each variable anchored at either end.  
 
At T=0, subjects were given access to a high protein meal which they were asked to 
consume within 10 minutes. Baseline plasma and serum were assayed for routine 
clinical chemistry (liver and kidney function, calcium and electrolytes).  Plasma levels 
of amino acids and the appetite and metabolic function markers insulin, GLP-1, PYY 
and ghrelin were measured at baseline and subsequent time points.  Blood samples 
were collected into lithium heparin-coated tubes (International Scientific Supplies Ltd, 
Bradford, UK) containing 2000 kallikrein inhibitor units (0.2 mL) aprotinin (Trasylol, 
Bayer Schering Pharma, Berlin, Germany).  Samples immediately underwent 
centrifugation for 10 minutes at 4°C (Hettich Zentrifugen Rotina 420R), after which, 
plasma was separated immediately and stored at -20°C until analysis. Cannulae 
were flushed with 5 ml 0.9% saline after collecting each blood sample. Immediately 
prior to collection of the subsequent sample, 1 ml deadspace blood was collected 
and discarded. 
 
 
Figure 2.1. A schematic representation of a study day for Part A of “The effect 
of L-cysteine on appetite in humans”. 
× represents time points at which blood samples and visual analogue scales (VAS) were 
collected.   
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2.4. Part B: Effect of oral amino acid administration on circulating levels of 
specific amino acids 
 
After the screening appointment, subjects were then asked to attend 5 study 
sessions, at least one week apart, during which they received either a vehicle 
control, a dose of L-cysteine (0.04 g/kg or 0.07 g/kg) or a dose of L-glycine (0.04 
g/kg or 0.07 g/kg). A schematic diagram giving an overview of Part B of the study 
can be seen in figure 2.2.  
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Figure 2.2. A schematic representation of the time-course of Part B of the study “The effect of L-cysteine on appetite in 
humans”. 
Following the initial recruitment, subjects attend a screening to deem if they are suitable for the study, followed by 5 study visits for those 
suitable.  × represent each study visit. 
 
 
 
 
 
 
Recruitment Screening 
Screening 
• Full medical and drug 
history 
• Blood screening 
• Baseline anthropometrics 
• BP and pulse 
• Psychological questionnaires 
• Pregnancy test 
Study period 
       = Study day 
• Pregnancy test 
• Anthropometrics 
• BP and pulse 
• Amino acid/control ad ministration 
• Visual analogue scales 
• Fasting and post-prandial gut hormone profile 
• Measures of glucose homeostasis 
1 2 3 4  Weeks 5 
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The study was conducted as described for part A above, except at T=0, subjects 
were given a dose of vehicle control, L-cysteine (0.04 g/kg or 0.07 g/kg) or L-glycine 
(0.04 g/kg or 0.07 g/kg), which they were asked to consume within 10 minutes 
instead of the high protein meal.  A schematic representation of a study day for Part 
B is illustrated in Figure 2.3. 
 
 
 
 
Figure 2.3. A schematic representation of a study day for Part B of “The effect 
of L-cysteine on appetite in humans”. 
 × represents time points at which blood samples and visual analogue scales (VAS) were 
collected.  
 
 
2.5. Part C: Effect of specific oral amino acid administration on ad libitum 
food intake 
 
After the screening appointment, subjects were asked to attend 6 study sessions, 
each at least 1 week apart, during which they would receive either vehicle control or 
a dose of L-glycine (0.04 g/kg or 0.07 g/kg) or L-cysteine (0.04 g/kg or 0.07 g/kg). 
The study was conducted in a single-blinded fashion. On their first visit, subjects 
always received vehicle control after an overnight fast. This protocol was an identical 
protocol to that used for the subsequent fasted visits, and was intended to 
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acclimatise the subject to the clinical environment and to experimental procedures.  
Results from the first vehicle control visit were not included in the analysis. Following 
the first vehicle control visit, subjects were randomly assigned to receive vehicle 
control, cysteine 0.04 g/kg, cysteine 0.07 g/kg, glycine 0.04g/kg or glycine 0.07g/kg.  
An overview of Part C can be seen in figure 2.4.  Doses were based on the results of 
Part B.  They did not exceed a dose of 7 grams, with a dose of up to 20 grams 
demonstrated to be safe (Davis et al., 1972, Carlson et al., 1989). 
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Figure 2.4. A schematic representation of the time-course of Part C of the study “The effect of L-cysteine on appetite in 
humans”. 
Following the initial recruitment, subjects attend a screening to deem if they are suitable for the study, followed by 6 study visits for those 
suitable.  × represent each study visit. 
 
 
Recruitment Screening 
Screening 
• Full medical and drug history 
• Blood screening 
• Baseline anthropometrics 
• BP and pulse 
• Psychological questionnaires 
• Pregnancy test 
• Test meal sampling 
• Issue 24 hour Food diary 
Study period 
       = Study day 
• Pregnancy test 
• Anthropometrics 
• BP and pulse 
• Food diary 
• Amino acid/control ad ministration 
• Ad libitum test meal 
• Visual analogue scales 
• Fasting and post-prandial gut hormone profile 
• Measures of glucose homeostasis 
1 2 3 4  Weeks 5 6 
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The study was conducted as described for part B above, except at T=60, 
subjects were given a buffet meal consisting of the preferred test meal 
decided at the screening. A schematic representation of a study day for Part 
C is illustrated in Figure 2.5.  The timing of the meal was chosen to 
correspond with the time at which there were optimal circulating amino acid 
concentrations post-consumption in Part B and based upon hunger and 
fullness data of the VAS obtained in Part B. Subjects were asked to eat until 
they were comfortably full.  Water was freely available during the mealtime.  
The meal was served with the curtains drawn around each subject for 30 
minutes, and consisted of either a macaroni cheese (631 kJ/100g) or a 
chicken korma with rice (653 kJ/100g).  The macronutrient content for both 
meals is described in Table 2.1. Each subject had previously decided on 
their choice of meal during their screening visit; they were subsequently 
served the same meal during each of their study visits. Food was weighed 
pre- and post-consumption. Energy intake was calculated from the weight of 
food consumed. Blood samples and a VAS were taken at the time points 
indicated in figure 2.5. The time points used were based on the results of Part 
B. Amino acids and hormones were measured as described above. 
 
Nutrition (per 100g) 
 
Macaroni cheese Chicken korma & rice 
Energy 631kJ 
151kcal 
653kJ 
156kcal 
Protein 7.0g 7.2g 
Carbohydrate 14.0g 14.4g 
Total sugars 1.0g 3.0g 
Starch 13.0g 11.4g 
Fat 7.4g 7.7g 
Salt 0.50g 0.53g 
 
Table 2.1. Macronutrient content for study meals used in Part C of the study 
“The effect of specific amino acids on appetite”.   
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Figure 2.5.  A schematic representation of a study day for Part C of the 
study “The effect of L-cysteine on appetite in humans”. 
× represents time points at which blood samples and visual analogue scales (VAS) 
were collected.   
 
 
2.6. Amino acid assay 
 
Amino acids were measured by the Department of Chemical Pathology at 
Imperial College Healthcare NHS Trust using a dedicated amino acid analyser 
(JEOL AminoTac), which used automated high performance cation exchange 
analysis. Underivatised amino acids were separated on a cation exchange 
resin column based upon net charge of particular amino acids.  
 
 
2.7. Plasma hormone assays 
 
2.7.1. PYY 
PYY-like immunoreactivity was measured with a previously established 
specific and sensitive in-house radioimmunoassay (Adrian et al., 1985).  The 
antiserum (Y21) was produced in rabbits against synthetic porcine PYY 
coupled to bovine serum albumin by glutaraldehyde and used at a final 
dilution of 1:50,000. This antibody cross-reacts fully with both PYY3-36 and 
PYY1-36, but not with pancreatic polypeptide, neuropeptide Y, or other known 
 36 
gastrointestinal hormones. The 125I PYY was prepared by the iodogen method 
(Wood et al., 1981) and purified by reverse phase high pressure liquid 
chromatography (RP-HPLC). The specific activity of the 125I PYY label was 54 
Bq/fmol. The assay was performed in total volume of 0.7 ml of phosphate 
buffer  (0.05M Na2HPO4.2H2O, 0.006M KH2PO4, 0.01M C10H14H2O8Na2.2H2O, 
0.008M NaN3) (pH 7.3±0.1) containing 0.3% bovine serum albumin. The 
assay was incubated for three days at 4ºC before separation of the free and 
antibody bound label by goat anti-rabbit antibody.  Samples were pre-
incubated for at least 60 minutes with 100μl of goat anti-rabbit solid-phase 
secondary antibody (Pharmacia Diagnostics AB, Uppsala, Sweden). 
Immediately prior to centrifugation, 500μl of 0.01% Triton-X-100 solution and 
100μl polyethylene glycol (PEG) (1:1) was added to each tube. The samples 
were then centrifuged at 1,500g at 4°C for 20 minutes. Bound and free label 
were separated and both the pellet and supernatant counted for 180 seconds 
in a γ-counter (model NE1600 (Thermo Electron Corporation, San Jose, 
California, U.S.A.)). PYY concentrations in the samples were calculated using 
a non-linear plot (RIA software, Thermo Electron Corporation) and the results 
calculated with reference to the standard. The detection limit of the assay was 
2.5 pmol/l, with an intra-assay coefficient of variation of 5.8 %. All samples 
were assayed in one assay to avoid inter-assay variation. 
 
2.7.2. GLP-1 
GLP-1- like immunoreactivity was measured by a specific and sensitive in-
house radioimmunoassay, previously established (Kreymann et al., 1987). 
The antibody was produced in rabbits against GLP-1 coupled to bovine serum 
albumin. The antibody cross-reacted 100% with all amidated forms of GLP-1 
but did not cross react with glycine extended forms [GLP-11-37 and GLP-17-37] 
or any other known pancreatic or gastrointestinal peptide. 125I-GLP-1 was 
prepared by the iodogen method (Wood et al., 1981) and purified by RP-
HPLC.  The specific activity of the 125I GLP-1 label was 48 Bq/fmol. The assay 
was performed in a total volume of 0.7 ml of sodium barbitone buffer (0.05M 
C8H11N2O3Na, 0.005M NaN3) (pH 8) containing 0.3 % bovine serum albumin 
(BSA). The assay was incubated for three days at 4ºC before separation of 
the free and antibody bound label by charcoal absorption. The free fraction 
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was separated using 4mg of charcoal per tube suspended in phosphate buffer 
with gelatine (0.0625mM gelatine, 0.05M Na2HPO4.2H2O, 0.006M KH2PO4, 
0.01M C10H14H2O8Na2.2H2O, 0.008M NaN3), added immediately prior to 
centrifugation.  The samples were then centrifuged at 1,500g at 4ºC for 20 
minutes. Bound and free label were separated, counted and analysed as 
described above. The limit of detection was 7.5 pmol/l with an intra-assay 
variation of 5.4%. All samples were assayed in one assay to avoid inter-assay 
variation. 
 
2.7.3. PP 
Human plasma PP concentrations were measured using a specific and 
sensitive RIA (Adrian et al., 1976).  An antiserum against human PP was 
produced in rabbits and the radiolabelled PP prepared by the iodogen method 
(Adrian et al., 1976).  It detects human PP fully but does not cross-react with 
any other known gastrointestinal hormone.  125I-labelled PP was prepared by 
the iodogen method (Wood et al., 1981) and purified by HPLC.  The specific 
activity of the 125I PP label was 54 Bq/fmol.  The assay was performed in a 
total volume of 0.7ml of phosphate buffer (0.06M) (pH 7.2) containing 0.3 % 
BSA.  The assay was incubated for 4 days at 4ºC before being separated, 
counted and analysed as described above for GLP-1. All samples were 
assayed in one assay to avoid inter-assay variation. 
 
2.7.4. Ghrelin 
Human plasma ghrelin concentrations were measured using a specific and 
sensitive enzyme-linked immunosorbent assay (ELISA) (Merck Millipore, 
Billerica, MA, USA).  Plasma was separated by centrifugation as described 
above, acidified with HCl to a final concentration of 1N (Hosoda et al., 2004), 
frozen and stored at -20C. The assay was carried out as per manufacturer‟s 
instructions. 
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2.8. Statistical analysis 
 
Combined data are shown as the mean ± standard error of the mean (SEM).  
Comparisons of energy intake were by one-way analysis of variance 
(ANOVA), followed by a post hoc Dunnett‟s test.  Comparisons of VAS scores 
were by one-way ANOVA, followed by a post hoc Dunnett‟s test.  The 
threshold for statistical significance in each case was set at p<0.05. Analyses 
were performed using Prism version 5.01 software (Graphpad Software, San 
Diego, CA, USA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39 
 
 
Chapter 3  
Results 
 40 
The clinical characteristics of the recruited subjects are summarized in Table 
3.1.  No serious adverse events were experienced by any of the subjects. 
 
 
 
Table 3.1. Baseline characteristics of the 12 participants recruited for Parts A-
C.  Data represent the mean ± SEM.  BMI: body mass index. 
 
 
3.1. To establish physiological levels of circulating amino acids 
following a high protein meal (Part A) 
 
3.1.1. Amino acid analysis  
Following consumption of the high protein meal, plasma cysteine levels 
increased from baseline, with peak levels achieved at 45 minutes after 
administration, and remained raised 150 minutes after administration.  For the 
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5 subjects who consumed the high protein meal, plasma cysteine 
concentrations are shown in figure 3.1 below.  
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Figure 3.1. Plasma cysteine concentrations (µmol/L) following a high 
protein meal. 
Five healthy subjects consumed a high protein meal (400g of cooked chicken breast 
consisting of 93.2g protein, 1.6g carbohydrate and 5.2g fat) at t=0, following an 
overnight fast.  During the study, subjects had blood samples taken every 15 minutes 
to measure plasma cysteine concentration.  All values represent group mean ± SEM.    
 
 
3.1.2. VAS analysis 
Following consumption of the high protein meal, subjects felt less hungry and 
fuller, with a sharp fall in hunger at 15 minutes (Figure 3.2 (A)) and a rise in 
fullness at 15 minutes (Figure 3.2 (B).  This effect on hunger appeared 
sustained for the time period of the study (150 minutes).  Similarly, subjects 
did not feel like eating after 15 minutes (Figure 3.2 (C,D), and again this effect 
lasted throughout the study period.  There was no evidence of any lasting side 
effects with the high protein meal (Figure 3.3 (A-E)).  
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Figure 3.2. Visual analogue scale ratings following a high protein meal. 
Five healthy subjects consumed a high protein meal (400g of cooked chicken breast 
consisting of 93.2g protein, 1.6g carbohydrate and 5.2g fat) following an overnight 
fast.  During the study, subjects completed 100 mm visual analogue scale 
questionnaires every 15 minutes.  A, How hungry do you feel?  B, How full do you 
feel? C, How pleasant would it be to eat? D, How much could you eat?  All values 
represent group mean ± SEM.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B How hungry do you feel? 
 
C
 
How pleasant would it be to eat? 
 
D How much could you eat? 
How full do you feel? A 
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Figure 3.3. Visual analogue scale ratings following a high protein meal. 
Five healthy subjects consumed a high protein meal (400g of cooked chicken breast 
consisting of 93.2g protein, 1.6g carbohydrate and 5.2g fat) following an overnight 
fast.  During the study, subjects completed 100 mm visual analogue scale 
questionnaires every 15 minutes. A, How sick do you feel? B, How warm do you 
feel? C, How irritable do you feel? D, How anxious do you feel? E, How sleepy do 
you feel?  All values represent group mean ± SEM.   
 
 
 
3.2. To determine circulating levels of amino acids following oral 
administration of cysteine, glycine control or vehicle control 
 
 
How sick do you feel? 
 
A
 
B
 
 
How warm do you feel? 
C
 
 
How irritable do you feel? D
 
 
How anxious do you feel? 
E
 
 
How sleepy do you feel? 
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3.2.1. Amino acid analysis  
Following consumption of oral cysteine (0.04g/kg), plasma cysteine levels 
increased from baseline, with peak levels achieved at 60 minutes after 
administration, and remained raised at 150 minutes after administration.  For 
5 subjects, plasma cysteine concentrations following administration of 
0.04g/kg of cysteine are shown in figure 3.4 below.   
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Figure 3.4. Plasma cysteine concentrations (µmol/L) following 
administration of cysteine. 
Five healthy subjects consumed 0.04g/kg of cysteine at t=0, following an 
overnight fast.  During the study, subjects had blood samples taken every 15 
minutes to measure plasma cysteine concentration.  These levels are 
compared to those found following administration of the high protein meal.  All 
values represent group mean ± SEM.   
  
 
3.2.2. VAS analysis 
Following oral consumption of vehicle, glycine (0.04g/kg) and cysteine 
(0.04g/kg), VAS were measured as shown in figure 3.5 (A-H) below.  There 
was no difference by ANOVA or area under the curve (AUC) in hunger, 
fullness and a need to eat between the groups.  In addition, there was no 
difference in any ill-effects caused by the amino acids (Figure 3.6 and 3.7) 
except for a small increase in anxiety with cysteine (figure 3.7 (A-B).    
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Figure 3.5. Analysis of VAS ratings of 7 subjects following administration of 
vehicle, glycine or cysteine. 
Subjects consumed vehicle, glycine (0.04g/kg) or cysteine (0.04g/kg) at t=0, following an 
overnight fast.  During the study, subjects completed 100 mm visual analogue scale 
questionnaires relating to hunger, nausea and fullness.  A, How hungry do you feel? B, AUC 
for How hungry do you feel? C, How full do you feel? D, AUC for How full do you feel? E, 
How pleasant would it be to eat? F, AUC for How pleasant would it be to eat? G, How much 
could you eat? H, AUC for How much could you eat? No differences by ANOVA.  All values 
represent group mean ± SEM.   
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Figure 3.6. Analysis of VAS ratings of 7 subjects following 
administration of vehicle, glycine or cysteine. 
Subjects consumed vehicle, glycine (0.04g/kg) or cysteine (0.04g/kg) at t=0, following 
an overnight fast.  During the study, subjects completed 100 mm visual analogue 
scale questionnaires relating to hunger, nausea and fullness.  A, How sick do you 
feel? B, AUC for How sick do you feel? C, How warm do you feel? D, AUC for How 
warm do you feel? E, How irritable do you feel? F, AUC for How irritable do you feel? 
No differences by ANOVA.  All values represent group mean ± SEM 
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Figure 3.7. Analysis of VAS ratings of 7 subjects following 
administration of vehicle, glycine or cysteine. 
Seven healthy subjects consumed vehicle, glycine (0.04g/kg) or cysteine (0.04g/kg) 
at t=0, following an overnight fast.  During the study, subjects completed 100 mm 
visual analogue scale questionnaires relating to hunger, nausea and fullness.  A, 
How anxious do you feel? B, AUC for anxious do you feel? C, How sleepy do you 
feel? D, AUC for How sleepy do you feel?  ** p<0.01. All values represent group 
mean ± SEM 
 
 
3.3. To determine circulating levels of amino acids following oral 
administration of a higher dose of cysteine, glycine control or vehicle 
control 
 
3.3.1. VAS analysis 
Following oral consumption of vehicle, glycine (0.07g/kg) and cysteine 
(0.07g/kg), VAS were measured as shown in figure 3.8 below.  There was a 
reduction in the AUC for “How hungry do you feel?” (p<0.05) (B), “How 
pleasant would it be to eat?” (D), “How much could you eat?” (p<0.05) (F). 
There was no difference by ANOVA or AUC in fullness (Figure 3.8(G,H)) 
between the groups.  There was no difference in ill effects caused by the 
amino acids (Figure 3.9 and 3.10).    
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Figure 3.8. Analysis of VAS ratings of 7 subjects following administration of 
vehicle, higher dose of glycine or cysteine. 
Seven healthy subjects consumed vehicle, glycine (0.07g/kg) or cysteine (0.07g/kg) at t=0, 
following an overnight fast.  During the study, subjects completed 100 mm visual analogue 
scale questionnaires relating to hunger, nausea and fullness. A, How hungry do you feel? B, 
AUC for How hungry do you feel? C, How full do you feel? D, AUC for How full do you feel? E, 
How pleasant would it be to eat? F, AUC for How pleasant would it be to eat? G, How much 
could you eat? H, AUC for How much could you eat? * p<0.05. All values represent group 
mean ± SEM.   
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Figure 3.9. Analysis of VAS ratings of 7 subjects following 
administration of vehicle, higher dose of glycine or cysteine. 
Seven healthy subjects consumed vehicle, glycine (0.07g/kg) or cysteine (0.07g/kg) 
at t=0, following an overnight fast.  During the study, subjects completed 100 mm 
visual analogue scale questionnaires relating to hunger, nausea and fullness. A, How 
sick do you feel? B, AUC for How sick do you feel? C, How warm do you feel? D, 
AUC for How warm do you feel? E, How irritable do you feel? F, AUC for How 
irritable do you feel? No differences by ANOVA.  All values represent group mean ± 
SEM 
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Figure 3.10. Analysis of VAS ratings of 7 subjects following 
administration of vehicle, glycine or cysteine. 
Seven healthy subjects consumed vehicle, glycine (0.07g/kg) or cysteine (0.07g/kg) 
at t=0, following an overnight fast.  During the study, subjects completed 100 mm 
visual analogue scale questionnaires relating to hunger, nausea and fullness. A, How 
anxious do you feel? B, AUC for anxious do you feel? C, How sleepy do you feel? D, 
AUC for How sleepy do you feel? No differences by ANOVA.  All values represent 
group mean ± SEM. 
 
 
 
3.4. To determine gut hormone levels following oral administration of 
cysteine, glycine control or vehicle control 
 
Following oral consumption of vehicle, glycine (0.04g/kg) and cysteine 
(0.04g/kg), GLP-1, PYY, PP and ghrelin were measured.  There was no 
difference by ANOVA or AUC in any of the hormones measured (Figure 3.11 
(A-H). 
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Figure 3.11. Analysis of gut hormones of 5-6 subjects following 
administration of vehicle, glycine or cysteine. 
Five to six healthy subjects consumed vehicle, glycine (0.04g/kg) or cysteine 
(0.04g/kg) at t=0, following an overnight fast.  During the study, blood samples were 
taken serially to determine gut hormone levels.  No differences by ANOVA. All values 
represent group mean ± SEM. 
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3.5. To determine gut hormone levels following oral administration of 
a higher dose of cysteine, glycine control or vehicle control 
 
Following oral consumption of vehicle, glycine (0.07g/kg) and cysteine 
(0.07g/kg), GLP-1, PYY, PP and ghrelin were measured.  There was a 
significant reduction in AUC for PP (p<0.05) when compared to both vehicle 
and glycine (Figure 3.12 (F)) but no difference by ANOVA (Figure 3.12 (E)).  
There was no difference by ANOVA or AUC in GLP-1 or PYY (Figure 3.12 (A-
D). 
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Figure 3.12. Analysis of gut hormones of 5-6 subjects following 
administration of a higher dose of vehicle, glycine or cysteine. 
Five to six healthy subjects consumed vehicle, glycine (0.07g/kg) or cysteine 
(0.07g/kg) at t=0, following an overnight fast.  During the study, blood samples were 
taken serially to determine gut hormone levels. * p<0.05. All values represent group 
mean ± SEM. 
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3.6. To determine the effect of cysteine on food intake   
 
3.6.1. Ad libitum meal 
There was no significant difference between food intake at an ad libitum buffet 
lunch following consumption of vehicle, glycine or cysteine. For the 11 
subjects who participated, the mean energy intake was 3796.0 ± 518.9 kJ 
when they received vehicle, 4057.5 ± 555.0 kJ when they received glycine 
0.04g/kg and 3680.0 ± 638.0 kJ when they received cysteine 0.04g/kg. This is 
illustrated in figure 3.13 below.  
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Figure 3.13. Effect of vehicle, glycine and cysteine on ad libitum food 
intake. 
On each study day, vehicle glycine (0.04g/kg) or cysteine (0.04g/kg) was 
administered at t=0 min. An ad libitum buffet meal was given at t=60 min in order to 
measure energy intake on all study days. The energy intake during the ad libitum 
meal following each amino acid administration is shown as mean ± SEM for 11 
subjects.   
 
 
3.6.2. Food diary analysis 
There was no significant difference between food intake following the study 
visit based on food diary analysis following consumption of vehicle, glycine or 
cysteine. For the 9 subjects whose food diaries were complete and analysed, 
the mean energy intake on day 1 was 8221.9 ± 836.2 kJ when they received 
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vehicle, 8184.6 ± 735.2 kJ when they received glycine 0.04g/kg and 7651.4 ± 
933.2 kJ when they received cysteine 0.04g/kg, on day 2 was 8394.2 ± 
1090.4 kJ when they received vehicle, 9264.4 ± 1010.2 kJ when they received 
glycine 0.04g/kg and 8407.7 ± 1155.3 kJ when they received cysteine 
0.04g/kg. This is illustrated in figure 3.14 below. 
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Figure 3.14. Effect of vehicle, glycine and cysteine on 3 day food intake. 
Day 1 represents the day prior to the study visit.  Day 2 represents the day of the 
study visit.  Day 3 represents the day after the study visit.  A 3 day food diary was 
given prospectively to all subjects prior to each study visit to complete in order to 
estimate energy intake prior to, during and after the study. On each study day 
vehicle, glycine (0.04g/kg) or cysteine (0.04g/kg) was administered at t=0 min. An ad 
libitum meal was given during the study visit (day 2) and this data is included.  The 
energy intake for days 1-3 is shown as mean ± SEM for 9 subjects.   
 
 
3.7. To determine the effect of a higher dose of cysteine on food 
intake 
 
Unfortunately the 0.07g/kg dose of cysteine induced minor adverse effects 
(dizziness) in one subject who took part in the study and hence this dose was 
not investigated further.    
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Chapter 4  
Discussion
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The studies described in this thesis investigated the effect of L-cysteine on appetite 
in humans.  Studies from my laboratory had suggested L-cysteine had the largest 
anorectic effect of all of the proteinogenic amino acids in rodents. The results of my 
studies suggest that the higher dose of L-cysteine administered (0.07g/kg) may 
influence subjective measures of appetite. However, it was also associated with side 
effects in one subject.    
 
The time course of the increase in circulating plasma cysteine was determined 
following administration of the high protein meal (consisting of grilled chicken).  This 
meal resulted in a two-fold increase in mean plasma cysteine concentration from 
1.9µmol/L (mean of baseline samples at t=-15 and t=0) to 4.0µmol/L (at t=60).  The 
time course of the increase in circulating plasma cysteine was also determined 
following administration of oral cysteine.  Oral administration of cysteine (0.04g/kg) 
resulted in a much higher increase in mean plasma cysteine concentration (from 
2.6µmol/L (mean of baseline samples at t=-15 and t=0) to 29.5µmol/L (at t=60)) than 
the high protein meal.  These results demonstrate that any effects that cysteine may 
have on appetite are unlikely to reflect a physiological effect achieved by circulating 
cysteine.  However, it is possible that following a meal that cysteine acts in 
combination with other amino acid ligands of the GPRC6A receptor to mediate 
satiety physiologically.  
 
Peak plasma cysteine levels are achieved at t=60 minutes with both the high protein 
meal and with administration of 0.04g/kg of cysteine.  This was in contrast to plasma 
levels of all other amino acids measured (taurine, aspartate, threonine, serine, 
asparagine, glutamate, glutamine, glycine, alanine, valine, methionine, isoleucine, 
leucine, tyramine, phenylalanine, histidine, lysine, tryptophan, arginine, proline) 
following the high protein meal, which peaked between t=90 and t=105 (Appendix I).  
Plasma amino acid concentrations generally start to rise at t=30 for all amino acids 
except cysteine, alanine and glutamine where there is an increase from baseline by 
t=15 (Appendix I).  By t=30, plasma cysteine levels following the high protein meal 
have already more than doubled.  This rapid rise in plasma levels appears to be 
unique to cysteine, and does not occur with the other amino acids measured.      
From the visual analogue scales, the satiating effects of the high protein meal occur 
by t=30 minutes.  This suggests that these particular amino acids may be responsible 
for the satiating effects of the high protein meal.  Alanine and cysteine are both 
amino acid ligands of the GPRC6A receptor.   
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The high protein meal reduced appetite, as demonstrated by the results of the visual 
analogue scales.  There was a sustained effect over the time course of the study 
(ending at t=150).  The satiating effect of protein on appetite has previously been 
demonstrated in numerous other studies (Bertenshaw et al., 2008, Crovetti et al., 
1998, Porrini et al., 1997, Latner and Schwartz, 1999). In addition, the satiating effect 
of protein has been demonstrated to be greater than that resulting from the ingestion 
of other macronutrients (Porrini et al., 1997, Reid and Hetherington, 1997, Trigazis et 
al., 1997, Bensaid et al., 2002, Anderson and Moore, 2004, Halton and Hu, 2004).    
 
At the lower doses of amino acids (0.04g/kg), there were no significant effects on 
subjective measures of appetite between treatments.  There was a trend towards 
significance (p=0.0875) in reduction of mean AUC when subjects were questioned on 
“How much could you eat?” with cysteine when compared to glycine.  Interestingly, at 
the higher dose of cysteine (0.07g/kg), there was a significant reduction in mean 
AUC when subjects were questioned on “How hungry do you feel?” (p<0.05), “How 
pleasant would it be to eat?” (p<0.05) and “How much could you eat? (p<0.05).  This 
suggests that this dose of cysteine can reduce appetite.    
 
Visual analogue scales have been shown to be a valid and reproducible measure of 
appetite (Flint et al., 2000a) and are used extensively in appetite research.   The 
questions on the VAS used in these studies correlate with hunger (“How hungry do 
you feel?”), fullness (“How full do you feel?”), prospective food consumption (“How 
much could you eat?”) and desire to eat (“How pleasant would it be to eat?”).  The 
predictive validity of subjective motivation to eat (as determined by desire to eat, 
hunger, fullness and prospective consumption) on VAS has been studied, with all of 
these above reported to predict subsequent energy intake (Flint et al., 2000a).  
Another study has suggested that the responses to the scales for desire to eat and 
prospective consumption both accurately predict forthcoming food intake (Barkeling 
et al., 1995).  This suggests these parameters in the VAS are the most useful 
subjective measures of appetite.  
 
The VAS also serve to elucidate any ill effects related to the study treatment.  
Macronutrients can cause nausea at high doses (Chapman et al., 1999, Williamson 
et al., 2005) and such feelings could potentially contribute to any effects that cysteine 
has on appetite. However, the VAS results suggest that cysteine (at both doses) did 
not induce nausea.  There was a significant increase in anxiety with the lower dose 
of cysteine when compared to glycine (0.04g/kg). However the absolute difference 
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was small, and may reflect that most subjects received cysteine at their very first 
study visit, and hence were perhaps more anxious as a result of this.  This finding is 
unlikely to be of clinical relevance, particularly as there was no difference with the 
higher dose of cysteine.     
 
Although energy intake following administration of cysteine (0.04g/kg) was lower 
compared to glycine, the difference was very small, and was not statistically 
significant.  Unfortunately the higher dose of cysteine was not investigated in the 
energy intake study as one subject experienced adverse effects (dizziness).  
Cysteine is actively transported across the blood brain barrier (Hawkins et al., 2006) 
and hence the adverse effect may be related to a central effect of cysteine at the 
higher dose (0.07g/kg).  Previous studies on oral cysteine where such side-effects 
have been reported have used higher doses (up to 20g) (Davis et al., 1972) 
compared to the doses administered here (maximum 6.5g).    
 
Thus my studies have been unable to demonstrate an effect of cysteine on energy 
intake, but suggest that cysteine may influence subjective measures of appetite.  The 
mechanism for this effect is unknown.  Cysteine is a ligand at the CaR, T1R1/T1R3 
receptor and the GPRC6A receptor; promiscuous L-amino acid sensing receptors 
present in the gut (Haid et al., 2011b, Daly et al., 2013, Chattopadhyay et al., 1998).  
In vitro work has shown that these receptors have a preference for particular classes 
of amino acids (Figure 4.1), thus in combination potentially responding to all 20 
proteinogenic L-amino acids (Wellendorph et al., 2009, Conigrave and Hampson, 
2006).  
 
The primary ligands of the CaR are calcium ions (Brown et al., 1993), although the 
receptor has also been shown to respond to L-amino acids, in particular aromatic 
amino acids such as L-tryptophan and L-phenylalanine (Conigrave et al., 2000). The 
CaR is insensitive to, or only weakly activated by, acidic, basic and branched-chain 
amino acids (Conigrave et al., 2000).  In a rat ex vivo small intestine preparation, the 
amino acid-stimulated release of GLP-1, PYY and gastric inhibitory polypeptide (GIP) 
was blocked by the CaR inhibitor Calhex 231 and augmented by the CaR agonist 
NPS-R568 (Mace et al., 2012), suggesting a role for the CaR in the release of gut 
hormones that can influence food intake.  However, the CaR knockout mouse 
phenotype suggests the primary role of CaR is in calcium homeostasis, rather than 
appetite (Ho et al., 1995).   
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The T1R1/T1R3 receptor has also been identified in the gut (Bezencon et al., 2007, 
Dyer et al., 2005). The mouse and human T1R1/T1R3 receptor differ in their relative 
affinities. The mouse receptor has a particular affinity for aliphatic (including 
branched chain), amidic, charged, sulphur- and hydroxyl-containing L-amino acids, 
but not the aromatic amino acids (Nelson et al., 2002, Zhao et al., 2003).  The human 
T1R1/T1R3 receptor has been shown to be more sensitive to L-glutamate and L-
aspartate than to other L-amino acids (Li et al., 2002).  It is worth noting that the 
T1R3 receptor also heterodimerises with the T1R2 receptor to form a sweet-sensing 
receptor (Nelson et al., 2001, Li et al., 2002).  The T1R2/T1R3 receptor and 
members of its transduction pathway have been shown to be present in the gut and 
to be involved in the glucose-stimulated release of GLP-1 (Jang et al., 2007, 
Margolskee et al., 2007).  The T1R2/T1R3 receptor can also increase glucose-
stimulated insulin secretion from pancreatic β-cells (Kyriazis et al., 2012). These data 
suggest that the taste receptor family is involved in hormone release. However, little 
is known regarding the role of T1R1/T1R3 in gut hormone release or in satiety. 
 
The GPRC6A receptor is an amino acid sensing receptor, which has been shown to 
induce GLP-1 secretion from an intestinal L cell line (Oya et al., 2013), thus 
presenting a mechanism by which this amino acid sensing receptor may mediate 
satiety.  Studies within the research groups on rodent models suggest that amino 
acid ligands of the GPRC6A receptor do not stimulate the release of GLP-1 and 
PYY.  The rat GPRC6A receptor is most responsive to L-ornithine, glycine and L-
citrulline (Wellendorph et al., 2007), the mouse GPRC6A receptor is most responsive 
to L-ornithine, L-arginine, L-lysine, L-serine, L-alanine, glycine, L-histidine and L-
cysteine, whilst the most active agonists at  the human GPRC6A receptor are the 
basic L-amino acids, L-arginine, L-lysine, and L-ornithine (Wellendorph et al., 2005).  
Any effects that have been seen are unlikely to be occurring via the GPRC6A 
receptor, as glycine strongly binds to this receptor, yet has little effect on appetite.  It 
is possible that one of the other amino acid sensing receptors may be mediating the 
effects e.g. the CaR which strongly binds L-cysteine compared to glycine. 
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Figure 4.1. L-Amino acid selectivity profiles at CaR, GPRC6A, and the 
T1R1/T1R3 heterodimer. 
Amino acids are grouped according to side-chain charge and polarity.  Data have 
been normalized to allow for comparison of relative amino acid preferences. The 
profile for CaR was generated by calculating the potentiating effect of each of the 20 
amino acids (at 10 mM concentrations) on the Ca2+ response. Numbers represent 
percentage response relative to that of L-histidine (100%) (Conigrave et al., 2000). 
The profile for GPRC6A is based on reported EC50 values of all 20 L-amino acids 
from mouse GPRC6A measured in the presence of 1mMCa2+  and 1 mM Mg2+ 
(Christiansen et al., 2007), here normalized to the L-lysine response (set to 100%). 
Mouse T1R1/T1R3 data originally in the form of “number of responsive cells” 
measured in the presence of 2.5mMIMP (Nelson et al., 2002) and converted to 
percentage normalized response by calculating the response relative to that of L-
cysteine (set to 100%) (taken from Wellendorph et al, 2009). 
 
 
 
These studies suggest that cysteine may exert a pharmacological effect in reducing 
appetite.  It is possible that this pharmacological effect reflects a physiological role; at 
physiological concentrations, cysteine, may act in concert with other L-amino acids, 
to mediate part of protein-induced satiety.   The mechanism by which cysteine 
reduces appetite remains unknown.  One possible explanation is the satiety effects 
are mediated by gut hormone release, however my results do not support that.  
There may be direct effects of cysteine on gut motility, which influence appetite.  
Cysteine may act directly on appetite centres in the brain to induce satiety.  Clinical 
studies are unlikely to elucidate the mechanism by which amino acids mediate 
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satiety and, if amino acid sensing receptors are involved, to determine the particular 
receptor responsible for these effects.  Pre-clinical studies using knockout mice or 
pharmacological antagonists are required to determine the receptors involved in 
protein and amino acid-induced satiety, and the mechanisms by which this process 
occurs. 
 
 
FUTURE WORK 
As cysteine may induce side effects as observed in one of my study participants, it is 
unlikely to be a good target for an anti-obesity agent. However, it may be possible to 
therapeutically exploit the mechanisms by which it influences appetite.  I intend to 
look at better amino acid ligands of the GPRC6A receptor, including L-arginine and 
L-lysine (Wellendorph et al., 2009) which animal data from within the laboratory 
strongly suggests may have anorectic effects.  
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APPENDIX I: Plasma concentrations of amino acids 
following a high protein meal 
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